/stocks — the workspaceLOADING
All JAGX SEC filings, by type → · Earnings date & implied move · Search inside filings
Jaguar Health, Inc. (JAGX) is a pharmaceutical preparations company. Piotroski F-Score 1/6. Next earnings projected around 2027-04-06 from JAGX's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind JAGX’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from JAGX’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on JAGX plus an auto-SWOT — built from JAGX's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate JAGX using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has JAGX been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as JAGX tagged it: revenue us-gaap:Revenues, net income us-gaap:ProfitLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
The fair-value line is JAGX’s own median P/E, P/S, P/B and P/FCF applied to each year’s fundamentals — the price its typical valuation would have implied. Where the solid line sits above the dashed one, the stock traded at a premium to its own history that year; below, a discount. This is a description of past valuation, computed from JAGX’s filings and price history — not a forecast and not investment advice. A stock can trade above or below its own median for years.
1 of 5 estimators could run on JAGX's filings. A band needs at least 2.
One estimator is a point estimate, not a range, so no band and no valuation label are published for JAGX. Below is everything that was checked, so the refusal can be read rather than taken on trust.
No sector peer set is priced for JAGX, so sector medians could not fill the gaps.
Every refusal recorded for JAGX → · How often we decline, and why →
Projected from JAGX's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentJAGX files or announces.
JAGX has sold off after 5 of its last 6 earnings reports.
Each figure is one earnings reaction — how much JAGX moved from the closing price the day before a report to the close the day after. Based on its last 6 reports.
Earnings reactions have been moderate.
JAGX has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+3.4% and -10.5%).
A more typical earnings reaction has been approximately ±4.6%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-19 | -10.5% |
| 2026-05-20 | +3.4% |
| 2026-04-07 | -2.7% |
| 2025-05-15 | -4.7% |
| 2025-03-31 | -4.8% |
| 2024-11-13 | -4.6% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
Total return including reinvested dividends, from JAGX’s adjusted closing prices. Past return is not a forecast and not investment advice.
No lawmaker has disclosed a trade in JAGX under the STOCK Act.
No tracked institution reported a position in JAGX in the latest 13F round.
No open-market Form 4 buys or sells reported for JAGX in the last ~6 months.
2 of the 2 checks that ran found nothing new for JAGX. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
Head office: San Francisco, California, United States · the company’s charter and its head office are in different states.
A charter change was filed after this. An 8-K filed 2026-10-05 reports an amendment to the company’s articles and a change to shareholder rights (Items 5.03 and 3.03). Reincorporations are reported that way, but so are routine changes such as a new series of preferred stock, and we have not read this one. If it moved the company, the next periodic report’s cover will show it.
Source: the cover page of Jaguar Health, Inc.’s 10-Q filed 2026-08-19, on EDGAR. Filings checked 2026-10-23. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works